Skip to Main Content

Paper Details

Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
J Clin Invest
112
2020
AR, ASXL3, CDH2, CRPC, CRPC-NE, CYLD, Circulating, Circulating tumor DNA, INSM1, NE, RB1, SPDEF, TP53, adenocarcinoma, androgen, androgen receptor, biopsy tissues, castration-resistant adenocarcinoma, castration-resistant neuroendocrine prostate cancer, cell free, cell free DNA, cfDNA, circulating tumor, clonal and subclonal tumor cell populations, ctDNA, differential sites, metastases, metastatic, metastatic prostate, metastatic tumor, patients, prostate adenocarcinoma, prostate cancers, tumor
Author NameAffiliation
Himisha BeltranDana Farber Cancer Institute
Himisha Beltran
Himisha BeltranDana Farber Cancer Institute
Himisha Beltran
Alessandro RomanelUniversity of Trento
Alessandro RomanelUniversity of Trento
Michael Sigouros
Mark A RubinCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Mark A Rubin
Mark A RubinCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Mark A Rubin
Andrea SbonerCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Andrea SbonerInstitute for Computational Biomedicine
Andrea SbonerCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Andrea SbonerInstitute for Computational Biomedicine
Jenny XiangCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Olivier ElementoInstitute for Computational Biomedicine
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Olivier ElementoInstitute for Computational Biomedicine
David M Nanus
David M NanusCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Scott T Tagawa
Scott T TagawaCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Francesca DemichelisUniversity of Trento
Francesca DemichelisCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Francesca DemichelisInstitute for Computational Biomedicine
Francesca DemichelisUniversity of Trento
Francesca DemichelisCaryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital
Francesca DemichelisInstitute for Computational Biomedicine
  • 1 - 30

Datasets

Release 1.2